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Abstract
Dietary fish oil-derived n-3 PUFA supplementation can increase muscle mass,
reduce oxygen demand during physical activity, and improve physical function
(muscle strength and power, and endurance) in people. The results from sev-
eral studies conducted in animals suggest that the anabolic and performance-
enhancing effects of n-3 PUFA are at least in part transcriptionally regulated.
The effect of n-3 PUFA therapy on the muscle transcriptome in people is
unknown. In this study, we used muscle biopsy samples collected during a
recently completed randomized controlled trial that found that n-3 PUFA
therapy increased muscle mass and function in older adults to provide a com-
prehensive assessment of the effect of n-3 PUFA therapy on the skeletal mus-
cle gene expression profile in these people. Using the microarray technique,
we found that several pathways involved in regulating mitochondrial function
and extracellular matrix organization were increased and pathways related to
calpain- and ubiquitin-mediated proteolysis and inhibition of the key anabolic
regulator mTOR were decreased by n-3 PUFA therapy. However, the effect of
n-3 PUFA therapy on the expression of individual genes involved in regulating
mitochondrial function and muscle growth, assessed by quantitative RT-PCR,
was very small. These data suggest that n-3 PUFA therapy results in small but
coordinated changes in the muscle transcriptome that may help explain the n-
3 PUFA-induced improvements in muscle mass and function.
Introduction
Dietary supplementation with fish oil-derived n-3 PUFA
has anabolic effects in muscle and can improve physical
performance in people with functional deficits. We
(Smith et al. 2015) and others (Broekhuizen et al. 2005;
Rodacki et al. 2012) have shown that n-3 PUFA therapy
increases muscle mass, strength and chair-rise ability in
older adults and endurance and peak work-load during
cycling exercise in persons with chronic obstructive
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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pulmonary disease. In addition, n-3 PUFA supplementa-
tion was found to reduce the oxygen demand during
physical activity in healthy, young adults (Peoples et al.
2008; Kawabata et al. 2014). The exact cellular mecha-
nism(s) responsible for the anabolic and performance
enhancing effect of fish oil-derived n-3 PUFAs in people
is still unclear. Studies conducted in animals (mice, rats,
and piglets) suggest that the anabolic and performance
enhancing effects of fish oil-derived n-3 PUFAs are at
least in part mediated by transcriptional changes in mus-
cle because n-3 PUFA treatment resulted in changes in
the gene expression of growth regulatory factors in mus-
cle that are consistent with anabolism (e.g., increased
MYOD1 and MYOG and decreased FOXO, MAFBX,
MURF1, and C5 proteasome subunit) (Castillero et al.
2009; Liu et al. 2013) and increased the gene expression
of master regulators of mitochondrial function
(PPARGC1A and UCP3) (Baillie et al. 1999; Mizunoya
et al. 2013; Johnson et al. 2015; Philp et al. 2015). We
are, however, not aware of any studies that evaluated the
effect of fish oil-derived n-3 PUFAs on changes in the
skeletal muscle transcriptome in people.
Therefore, the purpose of this study was to test the
hypothesis that fish oil-derived n-3 PUFA therapy
increases the expression of genes involved in regulating
mitochondrial function and anabolic and regenerative
pathways and decreases the expression of genes involved
in autophagy and atrophy in muscle. Accordingly, we
evaluated: (1) the expression of multiple gene set path-
ways known to be involved in regulating mitochondrial
function, cell growth, and structural support by using the
microarray technique; and (2) the gene expression of
PPARGC1A, PPARA, PDHA1, CPT1B, CS, UQCRC1,
UQCRC2, COX4I1, COX5B, and UCP3 (mitochondrial
biogenesis and function), and MYOD1, MSTN, FST
TIMP1, MMP14, MEGF10, GBARAP, LC3, ATOH8, and
FOXO3, MAFBX, MURF1 (muscle growth and regenera-
tion) using quantitative RT-PCR in skeletal muscle biop-
sies of older adults who participated in a 6-month long
double-blind, randomized controlled trial (RCT) that
evaluated the effect of n-3 PUFA therapy on muscle vol-
ume and strength (Smith et al. 2015).
Methods
Subjects
Muscle gene expression was examined in a subset of 20
healthy, 60–85-year-old men and women who partici-
pated in a larger, double-blind RCT evaluating the effect
of n-3 PUFA therapy on muscle mass and function
(Smith et al. 2015). We selected 10 subjects from the
treatment group who had the largest hypertrophic
response (change in thigh muscle volume) and 10 subjects
from the control group who were chosen to match the
subjects in the n-3 PUFA group on age, sex, body mass
index, and overall compliance to the protocol (e.g., %
pills consumed). We chose this “best responder”
approach to maximize the ability for detecting potentially
small n-3 PUFA-induced changes in muscle gene expres-
sion. Written informed consent was obtained from all
subjects before their participation in the study, which was
approved by the Human Research Protection Office and
the Clinical Research Unit Advisory Committee at Wash-
ington University School of Medicine in St. Louis, MO
and registered as trial number NCT01308957 in the clini-
caltrials.gov registry.
All subjects completed a comprehensive medical evalua-
tion, which included a history and physical examination,
a 75 g oral glucose tolerance test and standard blood
tests. Exclusionary criteria were: body mass index ≤18.5
or ≥35.0 kg/m2; unstable body weight (i.e., >2 kg change
during the last 6 months); exercise training (i.e., ≥1.5 h
of exercise per week); serious chronic disease (e.g., car-
diopulmonary disease, diabetes, chronic kidney disease,
cancer); modified Physical Performance Test score <17
out of 36 (Brown et al. 2000); treatment with medications
that could affect muscle mass and/or function (e.g.,
HMG-CoA reductase inhibitors, corticosteroids, or andro-
gen- or estrogen-containing compounds) within 1 year
before enrolling in the study; musculoskeletal or neuro-
muscular impairments that could interfere with exercise
testing; metal implants that could interfere with magnetic
resonance imaging; cognitive impairments that could
interfere with obtaining informed consent, treatment
adherence or testing procedures; use of tobacco products;
excessive alcohol consumption (>21 and >14 units per
week for men and women, respectively); consumption of
>2 servings of fatty fish per week; and use of fish oil
products.
Experimental protocol
Subjects in the n-3 PUFA group consumed four 1-gram
LOVAZA pills per day providing a total of 1.86 g eicos-
apentaenoic acid [20:5 n-3] and 1.50 g docosahexaenoic
acid [22:6 n-3] per day. Subjects in the control group
consumed four identical looking pills containing corn oil
per day. Both, the n-3 PUFA and corn oil pills were
kindly provided by GlaxoSmithKline plc (Research Trian-
gle Park, NC). Subjects were instructed to consume two
pills in the morning with breakfast and two in the eve-
ning with dinner. Compliance was assessed by pill count
at the end of the study and by changes in red blood cell
fatty acid composition (Smith et al. 2015). To help ensure
reliability of the pill count, subjects were given an excess
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number of pills and asked to return any remaining pills
at the end of the study. Study endpoints were assessed
before and after 6 months of treatment. All subjects were
instructed to maintain their habitual physical activity and
diet during the 6-month long n-3 PUFA and control
interventions.
Thigh muscle volume, intermuscular fat content, hand
grip and upper- and lower body 1-repetition maximum
(1-RM) strength (i.e., the maximal amount of weight that
each participant was able to lift just once), and red blood
cell n-3 PUFA content were measured during outpatient
visits to the Clinical Research Unit or the Center for Clin-
ical Imaging Research at Washington University School of
Medicine as previously described (Smith et al. 2015).
Briefly, thigh muscle volume and intermuscular fat con-
tent were quantified by using magnetic resonance imaging
(1.5-T superconducting magnet [Siemens, Iselin, NJ] and
Matlab software [Mathworks, Natick, MA]); hand grip
strength was measured using a Jamar hydraulic hand
dynamometer (Patterson Medical, Warrenville, IL); 1-RM
muscle strength was evaluated by using a multi-station
weight machine (Hoist Fitness Systems, Poway, CA) for
the following exercises (all bilateral): leg press, chest press,
knee extension, and knee flexion; and the fatty acid pro-
file of red blood cell lipids, which were extracted by using
the Folch method (Folch et al. 1957), was determined
using gas chromatography–mass spectrometry (GC-MS;
MSD 5973 System; Hewlett-Packard). A muscle biopsy
from the quadriceps femoris was obtained under local
anesthesia (lidocaine, 2%) using a Tilley Henkel forceps
(Smith et al. 2011a) for a minimum of 3 days after the
baseline and 6-month strength testing visits [median:
7 days, IQR: 5–9 days)]. Subjects were asked to refrain
from exercise for at least 3 days and fasted for 11  1 h
before the biopsy procedure. The duration of fasting and
time of day the biopsy was obtained was not different
before and after the intervention and between the inter-
vention and control groups. Muscle samples were rinsed
in ice-cold saline immediately after collection, cleared of
visible fat and connective tissue, frozen in liquid nitrogen
and stored at 80°C until final analysis.
Gene expression analyses
Microarray
Microarray analyses were performed with the GeneChip
Human Gene 1.0 ST array (Affymetrix, Santa Clara, CA).
Raw microarray data were normalized using a robust
multiarray analysis (RMA) method. To identify the path-
ways that were significantly altered by n-3 PUFA therapy,
normalized data were subjected to parametric analysis of
gene set enrichment (PAGE) by using the R statistical
software package (available at http://www.bioconduc-
tor.org) as previously described (Kim and Volsky 2005;
Yoshino et al. 2011; Fabbrini et al. 2015). Pathway gene
sets used in PAGE were obtained from http://
www.broad.mit.edu/gsea/msigdb/msigdb_index.html (C2:
curated gene sets collection). Z scores and P-values were
calculated for each gene set. Microarray data sets from
this study have been deposited in the NCBI Gene Expres-
sion Omnibus (GEO) database under accession number
GSE68894.
RT-PCR
RNA was isolated from frozen muscle samples by using
Trizol reagent (Invitrogen, Carlsbad, CA), quantified
spectrophotometrically (NanoDrop 1000, Thermo Scien-
tific, Waltham, MA) and reverse transcribed (High-Capa-
city cDNA Reverse Transcription Kit, Invitrogen). Gene
expression was determined using an ABI 7500 real-time
PCR system (Invitrogen) and SYBR Green Master Mix
(Invitrogen) as previously described (Smith et al. 2014;
Yoshino et al. 2014). The expression of each gene was
determined by normalizing the cycle threshold value of
each sample to the housekeeping control gene, ribosomal
protein RPLP0. Primer details are listed in Table 1.
Statistical analysis
Statistical analyses were carried out with SPSS (IBM,
Armonk, NY). All variables were tested for normality
using the Kolmogorov–Smirnov test and skewed data sets
were log-transformed for further analysis. Student’s t-test
was used to compare subject characteristics between the
n-3 PUFA and control groups at baseline. Repeated mea-
sures analysis of variance (ANOVA) was used to evaluate
the effect of n-3 PUFA therapy on thigh muscle volume,
intermuscular fat content, handgrip and 1-RM muscle
strength, red blood cell n-3 PUFA content, and muscle
gene expression determined by quantitative RT-PCR.
Tukey’s post hoc procedure was used to locate the differ-
ences when ANOVA identified a significant
group 9 treatment interaction. A P-value of ≤0.05 was
considered statistically significant. Data are presented as
mean  SEM or median [quartiles] for normally dis-
tributed and skewed data sets, respectively.
Results
Subject characteristics and compliance with
n-3 PUFA therapy
Baseline characteristics (age, body weight, body composi-
tion, muscle volume, intermuscular fat content, and
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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muscle function) of subjects in the n-3 PUFA and control
groups were not different (Table 2). Average compliance
with the dietary intervention, as judged by the leftover
pill count, was 95.4  1.3% in the n-3 PUFA and
93.5  2.0% in the control group. The red blood cell n-3
PUFA content increased by ~140% in the n-3 PUFA
group (from 6.0  0.3% to 14.0  0.4% of total fatty
acid content) and did not change in the control group
(5.5  0.4% of total fatty acid content before and
5.4  0.3% after, respectively).
Table 1. Sequence of primers used for RT-PCR.
Gene Accession No. Forward (F) and reverse (R) primer
ATOH8 NM_032827 F: 50- GCGAACGGCTATAAAACTTTCCG -30
R: 50- GCACAGCAAGATGCGAGGA -30
COX4I1 NM_001861 F: 50- CAGGGTATTTAGCCTAGTTGGC -30
R: 50- GCCGATCCATATAAGCTGGGA -30
COX5B NM_001862 F: 50- ATGGCTTCAAGGTTACTTCGC -30
R: 50- CCCTTTGGGGCCAGTACATT-30
CPT1B NM_001145134 F: 50- GCGCCCCTTGTTGGATGAT -30
R: 50- CCACCATGACTTGAGCACCAG -30
CS NM_004077 F: 50- TGCTTCCTCCACGAATTTGAAA -30
R: 50- CCACCATACATCATGTCCACAG -30
FOXO3 NM_001455 F: 50- CGGACAAACGGCTCACTCT -30
R: 50- GGACCCGCATGAATCGACTAT -30
FST NM_013409 F: 50- ACGTGTGAGAACGTGGACTG -30
R: 50- CACATTCATTGCGGTAGGTTTTC -30
GABARAP NM_007278 F: 50- AGAAGAGCATCCGTTCGAGAA -30
R: 50- CCAGGTCTCCTATCCGAGCTT -30
LC3 NM_032514 F: 50- AACATGAGCGAGTTGGTCAAG -30
R: 50- GCTCGTAGATGTCCGCGAT -30
MAFBX NM_148177 F: 50- GCCTTTGTGCCTACAACTGAA -30
R: 50- CTGCCCTTTGTCTGACAGAAT -30
MEGF10 NM_032446 F: 50- GAAGACCCTAATGTGTGTAGCC -30
R: 50- CAGTGCAGCTCGTGTAGTAAA -30
MMP14 NM_004995 F: 50- GGCTACAGCAATATGGCTACC -30
R: 50- GATGGCCGCTGAGAGTGAC -30
MSTN NM_005259 F: 50- TCCTCAGTAAACTTCGTCTGGA -30
R: 50- CTGCTGTCATCCCTCTGGA -30
MURF1 NM_032588 F: 50- CTTCCAGGCTGCAAATCCCTA -30
R: 50- ACACTCCGTGACGATCCATGA -30
MYOD1 NM_002478 F: 50- CGCCATCCGCTATATCGAGG -30
R: 50- CTGTAGTCCATCATGCCGTCG -30
PDHA1 NM_000284 F: 50- TGGTAGCATCCCGTAATTTTGC -30
R: 50- ATTCGGCGTACAGTCTGCATC -30
PPARA NM_001001928 F: 50- ATGGTGGACACGGAAAGCC -30
R: 50- CGATGGATTGCGAAATCTCTTGG -30
PPARGC1A NM_013261 F: 50- TCTGAGTCTGTATGGAGTGACAT -30
R: 50- CCAAGTCGTTCACATCTAGTTCA -30
TIMP1 NM_003254 F: 50- CTTCTGCAATTCCGACCTCGT -30
R: 50- ACGCTGGTATAAGGTGGTCTG -30
UCP3 NM_003356 F: 50- TGTTTTGCTGACCTCGTTACC -30
R: 50- GACGGAGTCATAGAGGCCGAT -30
UQCRC1 NM_003365 F: 50- GGGGCACAAGTGCTATTGC -30
R: 50- GTTGTCCAGCAGGCTAACC -30
UQCRC2 NM_003366 F: 50- TTCAGCAATTTAGGAACCACCC -30
R: 50- GGTCACACTTAATTTGCCACCAA -30
RPLP0 NM_001002 F: 50- GTGATGTGCAGCTGATCAAGACT -30
R: 50- GATGACCAGCCCAAAGGAGA -30
2016 | Vol. 4 | Iss. 11 | e12785
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Compared with the control group, 6 months of n-3
PUFA therapy increased thigh muscle volume by 10.3 
2.2% (P < 0.001), handgrip strength by 10.3  3.3%
(P < 0.01) and 1-RM muscle strength by 9.1  4.1%
(P < 0.05), and lowered intermuscular fat content by
11.5  5.2% (P < 0.05).
Effect of n-3 PUFA therapy on skeletal
muscle gene transcription
Gene expression profiling by microarray analyses
Several pathways involved in regulating mitochondrial
function, cell growth, and structural support were signifi-
cantly affected by n-3 PUFA therapy (Table 3). Pathways
associated with respiratory electron transport and oxida-
tive phosphorylation (mitochondrial function) and extra-
cellular matrix (ECM) organization (structural support)
were significantly increased and pathways related to cal-
pain- and ubiquitin-mediated proteolysis, mRNA transla-
tion, and inhibition of mTOR signaling were significantly
decreased by n-3 PUFA therapy (all P < 0.05). n-3 PUFA
therapy also increased several pathways related to
G-protein coupled receptor (GPCR) signaling (i.e.,
REACTOME_GPCR_LIGAND BINDING, REACTO-
ME_GPCR_ DOWNSTREAM_SIGNALING, and REAC-
TOME_SIGNALING_BY_GPCR; all Z-scores >3.8 and
P < 1.50E-04), which is one of the primary pathways of
n-3 PUFA action. Additional gene set pathways in
skeletal muscle that were significantly changed by n-3
PUFA therapy can be found in the online supporting
information.
Quantitative RT-PCR analysis of genes involved in
muscle mitochondrial function, hypertrophy,
atrophy, regeneration, and autophagy
n-3 PUFA treatment increased (P < 0.05) the gene
expression of UCP3 and UQCRC1 by ~30% and ~20%,
respectively (Fig. 1). PPARGC1A, PPARA, PDHA1,
CPT1B, CS, UQCRC2, COX4I1, and COX5B gene expres-
sion was unaffected by n-3 PUFA or control oil therapy
(Fig. 1). The expression of genes related to hypertrophy,
atrophy, regeneration, and autophagy was not affected by




(n = 10) P-value1
Age (years) 70  2 68  2 0.60
Blood pressure
Systolic (mm Hg) 127  4 125  3 0.67
Diastolic (mm Hg) 74  2 73  2 0.73
Plasma concentrations2
Triglycerides (mmol/L) 1.01  0.11 1.28  0.21 0.29
HDL-cholesterol (mmol/L) 1.48  0.11 1.79  0.16 0.14
LDL-cholesterol (mmol/L) 2.92  0.26 3.34  0.23 0.25
Glucose (mmol/L) 5.31  0.11 5.12  0.14 0.30
Glucose - 2 h post OGTT (mmol/L) 7.19  0.47 6.41  0.60 0.32
Body mass and composition
Body mass index (kg/m2) 25.3  1.2 26.5  1.4 0.53
Body mass (kg) 74.2  4.6 72.5  4.5 0.80
Body fat (kg) 22.9  2.8 25.7  2.3 0.46
Body fat (%) 30.7  3.0 35.2  1.8 0.23
Thigh muscle volume (cm3) 3225  190 3042  217 0.53
Thigh inter-muscle fat content (cm3) 39.3  7.0 46.3  3.9 0.39
Physical function
Handgrip strength (kg) 36  4 33  3 0.62
Leg press, 1-RM strength (kg) 48  4 47  4 0.88
Chest press, 1-RM strength (kg) 42  6 34  4 0.29
Knee extension, 1-RM strength (kg) 57  9 45  6 0.24
Knee flexion, 1-RM strength (kg) 53  6 44  5 0.21
Sum 1-RM strength (kg) 201  23 170  18 0.29
Values are mean  SEM. OGTT, oral glucose tolerance test; 1-RM, 1-repetition maximum.
1Comparison between groups was performed by using Student’s t-test for independent samples.
2Values (except for 2 h post OGTT) were obtained after an overnight fast.
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n-3 PUFA therapy and remained stable in both the n-3
PUFA and control groups during the 6 months treatment
period (Fig. 2).
Discussion
In this study, we provide a comprehensive assessment of
the effect of n-3 PUFA therapy on the skeletal muscle
gene expression profile to determine whether the benefi-
cial effects of n-3 PUFA on muscle mass and physical
function and performance (Broekhuizen et al. 2005; Peo-
ples et al. 2008; Rodacki et al. 2012; Kawabata et al. 2014;
Smith et al. 2015) might be transcriptionally regulated.
We found that several gene set pathways (assessed by
microarray analyses) involved in regulating mitochondrial
function and ECM organization were significantly
increased and pathways related to calpain- and ubiquitin-
mediated proteolysis and inhibition of the key anabolic
regulator mTOR were significantly decreased by n-3
PUFA therapy; however, the effect of n-3 PUFA therapy
on the expression of a select group of individual genes
involved in regulating mitochondrial function and muscle
growth, assessed by quantitative RT-PCR, was very small.
These findings suggest that n-3 PUFA therapy induces
subtle but coordinated changes in key gene set pathways
related to muscle structure, growth, and oxidative meta-
bolism that may help explain the anabolic and function
enhancing effects of n-3 PUFA therapy.
Although microarray analysis indicated that several
gene set pathways involved in regulating mitochondrial
function were increased by n-3 PUFA therapy, we only
found a significant effect of n-3 PUFA therapy for two
genes related to mitochondrial function using the RT-
PCR technique: UQCRC1 and UCP3. Several other mito-
chondrial genes were not affected by n-3 PUFA treatment.
The limited effect of n-3 PUFA therapy on the expression
of individual genes involved in mitochondrial function in
our study is consistent with the findings from several pre-
vious studies conducted in excised rodent muscles and
cultured muscle cell lines that found either a small
Table 3. Gene set pathways related to mitochondrial function, growth regulation, metabolism, and structural support in skeletal muscle that
were significantly changed by n-3 PUFA therapy.





























Positive Z-scores indicate an upregulation (increased gene expression) and negative values a downregulation (decreased gene expression) of
pathways.
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increase (Vaughan et al. 2012; Mizunoya et al. 2013;
Philp et al. 2015) or no effect (Lanza et al. 2013; Johnson
et al. 2015) of n-3 PUFA treatment on mitochondrial
gene expression in cell lines and rodent models. It is pos-
sible that the effect of n-3 PUFA may be specifically
related to the electron transport chain. Both UQCRC1 (a
component of mitochondrial complex III) and UCP3 are
key parts of the electron transport chain and all of the
mitochondrial pathways that were identified as being
upregulated by n-3 PUFA therapy in our microarray data
set were electron transport chain related. Moreover, fat-1
transgenic mice, which can convert n-6 PUFAs to n-3
PUFAs and therefore have increased endogenous n-3
PUFA availability, have an increased activity of complex
III and IV proteins in the electron transport chain (Hago-
pian et al. 2010). Reduced oxidative capacity and mito-
chondrial dysfunction are thought to play a key role in
the age-related decline of physical function (Hiona and
Leeuwenburgh 2008; Ibebunjo et al. 2013; Hepple 2014;
Barbieri et al. 2015) and even a small but consistent
increase in mitochondrial function genes may help
explain the n-3 PUFA-mediated increase in endurance
and oxygen demand and time to fatigue during physical
activity in people (Broekhuizen et al. 2005; Peoples et al.
2008; Peoples and McLennan 2010, 2014; Kawabata et al.
2014). In addition, posttranscriptional and/or posttransla-
tional modifications of mitochondrial gene products that
affect mitochondrial protein quality are likely also
involved in the beneficial effect of n-3 PUFA therapy on
physical function (Herbst et al. 2014; Johnson et al.
2015).
An increase in pathways related to ECM organization
potentially provides a new mechanism for the hyper-
trophic and strength enhancing effect of n-3 PUFA treat-
ment (Smith et al. 2015) because skeletal muscle ECM
provides structural integrity, regulates mechanotransduc-
tion, and coordinates cellular activities involved in muscle
development, maintenance, and regeneration (Lukashev
and Werb 1998; Osses and Brandan 2002; ten Broek et al.
2010; Hinds et al. 2011; Thomas et al. 2015). Indeed,
changes in muscle loading that lead to muscle hypertro-
phy or atrophy (e.g., resistance exercise training and
Figure 1. Skeletal muscle gene expression of key regulators of
mitochondrial biogenesis and function. Expression of individual
genes involved in mitochondrial biogenesis and function was
determined by quantitative RT-PCR before (white bars) and after
(black bars) corn oil or n-3 PUFA treatment (n = 10 per group). The
expression of genes of interest was normalized to the expression of
RPLP0. *Value significantly different from corresponding value in
the control group (P < 0.05 by post-hoc Tukey’s test). †Value
significantly different from corresponding value before treatment
(P < 0.01 by post hoc Tukey’s test). #ANOVA revealed a significant
main effect of group (P < 0.05). UPC3, UQCRC1, CS, PPARGC1A,
PPARA, PDHA1, CPT1B, UQCRC2, COX4I1, and COX5B are
presented as mean  SEM; are presented as median  quartiles.
UCP3, uncoupling protein 3; UQCRC1, ubiquinol-cytochrome c
reductase core protein I; CS, citrate synthase; PPARGC1A,
peroxisome proliferator-activated receptor gamma coactivator 1
alpha; PPARA, peroxisome proliferator-activated receptor alpha;
PDHA1, pyruvate dehydrogenase (lipoamide) alpha 1; CPT1B,
carnitine palmitoyltransferase 1B; UQCRC2, ubiquinol-cytochrome c
reductase core protein II; COX4I1, cytochrome c oxidase subunit
4I1; COX5B, cytochrome c oxidase subunit 5B.
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immobilization, respectively) are typically associated with
corresponding changes in ECM-related gene and protein
expression (Cros et al. 2001; Lecker et al. 2004; Urso
et al. 2006; Ogasawara et al. 2014; Hyldahl et al. 2015).
Moreover, the results from studies conducted in trans-
genic and knockout mouse models have shown that ECM
components are essential for muscle hypertrophy (Dahiya
et al. 2011; Zhang et al. 2015) and anabolic signaling
transduction during hypertrophy (Dahiya et al. 2011). In
line with this, negative regulators of mTOR signaling were
downregulated in this study and mTOR-mediated ana-
bolic signaling and protein synthesis were increased by n-
3 PUFA therapy in our previous study (Smith et al.
2011a). In addition, we found that calpain- and
ubiquitin-mediated proteolytic pathways were inhibited.
Suppression of calpain and ubiquitin/proteasome path-
ways by n-3 PUFA is consistent with the results obtained
from a series of studies conducted in various animal
models and in cultured muscle cells that demonstrate
decreased mRNA expression of MAFBX, MURF1, and C5
proteasome subunit and reduced calpain and proteasome
activity and rates of proteolysis after treatment with fish
oil-derived n-3 PUFAs (Whitehouse and Tisdale 2001;
Whitehouse et al. 2001, 2003; Castillero et al. 2009;
Supinski et al. 2010; Huang et al. 2011; Liu et al. 2013).
Accordingly, n-3 PUFA probably exert their anabolic
effect both via increasing protein synthesis and decreasing
protein breakdown. The reduction of pathways related to
Figure 2. Skeletal muscle gene expression of key regulators of hypertrophy, atrophy, regeneration, and autophagy. Expression of individual
genes involved muscle hypertrophy, regeneration, atrophy, and autophagy was determined by quantitative RT-PCR before (white bars) and
after (black bars) corn oil or n-3 PUFA treatment (n = 10 per group). The expression of genes of interest was normalized to the expression of
RPLP0. MYOD1, MURF1, MAFBX, TIMP1, MMP14, LC3, and GABARAP are presented as mean  SEM; MSTN, FST, FOXO3, and MEGF10 are
presented as median  quartiles. #ANOVA revealed a significant main effect of group (P < 0.05). MYOD1, myogenic differentiation 1; MSTN,
myostatin; FST, follistatin; FOXO3, forkhead box O3; MURF1, muscle-specific RING finger-1; MAFBX, muscle atrophy F-box; TIMP1, TIMP
metallopeptidase inhibitor 1; MMP14, matrix metallopeptidase 14; MEGF10, multiple EGF-like-domains 10; LC3, microtubule-associated protein
1 light chain 3 alpha; GABARAP, GABA(A) receptor-associated protein; ATOH8, atonal homolog 8 (Drosophila).
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mRNA translation in this study is most likely a reflection
of increased translation efficiency, which we have demon-
strated previously (Smith et al. 2011b), rather than
decreased capacity for protein translation.
With the exception of UCP3 and UQCRC1, we did
not detect significant changes in the expression of a
targeted set of individual genes (assessed by RT-PCR)
known to be involved in mitochondrial biogenesis and
muscle mass regulation. It is possible that our study
was underpowered to detect changes in the expression
of the other genes we measured. However, we carefully
selected genes that have been affected by n-3 PUFA
treatment in cell culture and animal models (White-
house and Tisdale 2001; Whitehouse et al. 2001; Smith
et al. 2004, 2005; Castillero et al. 2009; Huang et al.
2011; Vaughan et al. 2012; Liu et al. 2013) and evalu-
ated them in subjects who had the largest hypertrophic
response (i.e., increase in thigh muscle volume) during
n-3 PUFA treatment. Therefore, it is unlikely that we
did not detect biologically meaningful changes due to
the small sample size or a small physiological effect
size. It seems more likely that n-3 PUFA therapy has
minimal impact on the expression of individual genes
in muscle, but significantly changes biological pathways
that consist of a coordinated set of regulators, thereby
contributing to the improvement in skeletal muscle
mass and function.
In conclusion, the results from our study indicate that
the beneficial effects of n-3 PUFA on muscle mass and
function/physical performance may be in part transcrip-
tionally regulated and involves gene set pathways related
to mitochondrial function, structural support, and ana-
bolic signaling and proteolysis. Although the effect of n-3
PUFA therapy on the expression of individual genes was
small, a coordinated up- or downregulation of genes in
specific pathways, identified by using the microarray tech-
nique, could have significant effects on muscle mass and
function.
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